AstraZeneca PLC

AstraZeneca's prescription revenue is anchored by physician adoption and patient persistence across 16 established blockbusters, providing reasonable franchise-level forward visibility. Revenue is not contractual or backlog-based, and structured patent expirations across FY2026-FY2028 including US Farxiga exclusivity expiring April 2026 introduce gaps that pipeline launches are expected to fill but have not yet confirmed.

The Oncology segment represented approximately 43% of FY2025 total revenue, with BioPharmaceuticals at roughly 39% and Rare Disease at 16%. Within Oncology, no single product exceeds roughly 14% of group revenue (Tagrisso at approximately $7 billion of $58.7 billion), and multiple blockbusters span distinct indications, providing meaningful product-level diversification despite Oncology's segment dominance.

In FY2025, the United States accounted for approximately 35% of product revenue, Europe roughly 26%, China 11%, and Emerging Markets excluding China 15%, with no single country exceeding 40% of consolidated revenue. This spread across four material regions was maintained across FY2021-FY2025 including through the COVID-driven market dislocations of 2020, demonstrating structural rather than opportunistic diversification.

AstraZeneca's gross margin of 82% reflects IP-protected pharmaceutical pricing and provides a structurally high top line. Core R&D spending increased materially in FY2025 as the company invested in its late-stage pipeline, and the $50 billion US manufacturing and R&D commitment through 2030 implies significant proportional cost reinvestment alongside revenue growth, limiting operating leverage to a moderate level.

Oncology, rare disease, and cardiovascular medicines are mission-critical for patients with life-threatening or chronic conditions, producing strong physician and patient persistence across multi-year treatment durations. Across 16 blockbusters treating conditions such as EGFR-mutant lung cancer (Tagrisso) and heart failure with reduced ejection fraction (Farxiga), the repeat-prescription dynamic is non-discretionary, though revenue is transactional rather than contractual.